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ng author. Tel.: +44 161
ess: penny.hopwood@chSummary Quality of life (QOL) assessments of women entering a UK randomised
trial of adjuvant radiotherapy (START) were investigated to estimate the
independent effects on QOL of age, time since surgery, type of breast surgery,
chemotherapy and endocrine therapy. QOL was evaluated using the EORTC general
cancer QOL scale (EORTC QLQ-C30), breast cancer module (BR23), the Body Image
Scale (BIS) and the Hospital Anxiety and Depression Scale (HADS). Independent
effects of age and clinical factors were tested using multiple regression analysis.
A total of 2208 (mean age 56.9 years, range 26–87) consented to the QOL study prior
to radiotherapy; 17.1% had undergone mastectomy (Mx) and the remainder had
undergone a wide local excision (WLE). 33.3% had received adjuvant chemotherapy (CT)
and 56.7% were taking endocrine therapy (ET). Age had significant effects on QOL with
older and younger subgroups predicting poorer QOL for different domains. CT affected
most QOL domains and resulted in worse body image, sexual functioning, breast and arm
symptoms (o0.001). Mx was associated with greater body image concerns (po0.001),
and WLE with more arm symptoms (p ¼ 0.01). There were no effects of ET on QOL.
Women o50 years (proxy pre-menopausal) had worse QOL in respect of anxiety, body
image and breast symptoms but age and clinical factors had no effect on depression.
Overall, QOL and mental health were favourable for most women about to start
RT, but younger age and receiving CTwere significant risk factors for poorer QOL, and
so patients in these subgroups warrant further monitoring. Surgery had a limited
impact and ET had no effect on QOL.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
446 8004; fax: +44 161 446 8565.
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P. Hopwood et al.242Introduction effects on QOL of age and other primary treat-Women with primary breast cancer usually undergo
breast surgery plus adjuvant systemic treatments in
order to reduce the risks of local and distant
disease recurrence, but with the potential for
multiple effects on quality of life (QOL). The
overall psychosocial impact of these modern treat-
ments has been reported.1–8 Younger patients are
more likely to suffer adverse effects because of
induction of an early menopause and possible
infertility. Other reported problems have included
poor sexual functioning, altered body image,
fatigue and difficulty with shoulder and arm move-
ments. These effects may have an impact on QOL in
the longer term. Radiotherapy is known to have
late effects on normal tissues which could con-
tribute adversely to body image and related QOL
parameters but it is often impossible to attribute
QOL effects, such as breast symptoms, to a specific
adjuvant strategy in multimodal therapy.9–15 Ganz
and colleagues commented that women are gen-
erally well prepared for the acute toxicities of
breast cancer treatments but that clinicians have
limited information on the physical and psychoso-
cial sequelae of primary treatments, or the pattern
of recovery. This highlights the need for more
precise data on individual treatment effects and
interactions.16
The QOL protocol in the Standardisation of Breast
Radiotherapy Trial (START) trial will help address
these deficiencies, through its prospective design
and long term follow-up, by using patient assessed
measures of body image and QOL, and by identify-
ing the effects of individual treatments in multi-
modal therapy. The trial includes women of all ages
allowing the effect of age on QOL to be explored.
The purpose of the trial is to test the effects of
radiotherapy fractions 42.0 Gy on local tumour
control and late normal tissue response in the
breast area after tumour excision. The trial
comprises two randomised comparisons, namely
Trial A, which tests three fractionation schedules;
50Gy in 25 fractions (F) over 5 weeks versus two
dose levels of a test schedule giving 41.6Gy or
39Gy in 13 F over 5 weeks, and Trial B, which tests
the standard therapy (50Gy in 25 F) against a dose
level of 40Gy in 15 F over 3 weeks.17 Long-term
follow-up is now being completed and QOL will
form part of the outcome assessment of the
randomised comparison. Over 2000 women (450%
of trial participants) have been accrued to the QOL
study, making this the largest such investigation in
the UK. Prior to breaking the randomisation code,
we have undertaken this analysis to describe QOL in
the overall cohort of patients and to investigate thements, prior to starting radiotherapy, in order to
gauge the extent to which key domains such as
body image may be affected by other primary
treatments. The size of the database allows us to
explore the individual impact of type of surgery,
endocrine therapy (ET), chemotherapy (CT), as
well as examining age effects, whilst controlling for
time since surgery, on all QOL domains.
Aims of baseline analysis
To describe all aspects of QOL at baseline, i.e. prior
to undergoing radiation therapy.
To determine the impact on QOL of age, type of
breast surgery (Mx vs WLE), adjuvant CT and ET
whilst controlling for time elapsed since surgery.
These factors were selected to accurately deter-
mine the impact of primary breast cancer treat-
ment on QOL before radiotherapy, whilst taking
account of the fact that patients undergoing CT
would have a longer time between breast surgery
and radiotherapy compared with those proceeding
directly to radiotherapy. Age was included because
it is known to influence some aspects of QOL.
To compare women under 50 years with those aged
X50 in terms of QOL. These age-groups were chosen
to provide subgroups representing proxy pre- and
post-menopausal status in the analysis at baseline.Methods
Women prescribed postoperative radiotherapy for
early breast cancer attending the 35 centres
participating in the START trial were eligible for
the QOL study. A total of 4451 patients were
recruited into the START trial between 1999 and
2002. The protocol did not impose a limit on the
time between surgery and randomisation into the
trial, but there had to be a minimum of two weeks
between the end of chemotherapy and the start of
radiotherapy treatment. Patients from 31 of the
centres were recruited into the QOL study, after
obtaining written informed consent. To avoid
introducing bias from knowledge of randomised
treatment allocation, baseline QOL data were
collected prior to randomisation into the START
trial, together with demographic data.
QOL Measures
Standardized self-report QOL measures were used,
including the EORTC QLQ-C30,18 the EORTC BR23,19
the Body Image Scale (BIS),20 and the Hospital
Anxiety and Depression Scale (HADS).21 These
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QOL in early breast cancer 243measures were selected as they had been used
successfully in other national and European breast
cancer trials, allowing comparison of results.
The QLQ-C30 is a 30-item multi dimensional
cancer specific QOL scale made up of 5 functional
subscales (physical, role, emotional, cognitive, and
social functioning), together with 9 symptom sub-
scales/items (fatigue, nausea and vomiting, pain,
dyspnoea, insomnia, appetite loss, constipation,
diarrhoea, and financial difficulties). Two further
items assess global health and global quality of life.
The BR23 breast cancer module is designed to
capture effects due to treatment. Its 23 items are
organised into four symptom scales (systemic
therapy side effects, breast symptoms, arm symp-
toms, and upset by hair loss) and four functional
subscales (body image, sexual functioning, sexual
enjoyment, and future perspective).
The BIS is a 10-item scale designed for use with
cancer patients. Items cover change in physical and
sexual attractiveness, physical appearance when
dressed and naked, satisfaction with the body and
scars, body integrity and avoidance of people. The
BIS is widely used in national breast cancer trials
and psychosocial studies. The four body image
items in BR23 were taken from the 10-item scale
but there is no duplication of body image items in
the QOL assessment booklet.
The HADS is a 14-item scale designed for use in a
medical setting. It is the most widely used measure
of psychological distress in cancer patients and has
been used extensively in UK cancer therapy trials
over many years. It has the advantage over QOL
subscales that measure emotional functioning in
providing an estimate of the clinical level of distress
by applying threshold scores for normal, borderline
or probable case levels of anxiety or depression.
Additional protocol specific symptom items were
included to cover expected effects of radiotherapy
and will be reported later.
Scoring and statistical analysis
EORTC QLQ-C30 and BR-23
All items were scored using a 4-point response
scale, except for global health and global quality of
life, for which a 7-point range was used. For the
functional and global health/QL subscales, higher
scores indicate a better level of functioning,
whereas for the symptom scales, higher scores
represent more symptoms.
Summary scores were calculated according to the
EORTC manual.22 Summary statistics were calcu-
lated for baseline scores, according to categories of
type of surgery (Mx, WLE), time since surgery, CT,
ET and age. Subscale scores were comparedbetween groups of patients defined according to
age and the set of clinical variables tested using t-
tests and analysis of variance (ANOVA) as appro-
priate. In order to investigate the effect of
confounding on observed associations with QOL
scores, multiple regression was used, and the
significance of variables tested using the F-test from
an ANOVA that included all relevant independent
variables (surgery, time since surgery, CT, ET and
age). Hence the p-values from the F-test indicate
the significance of each variable after allowing for
the effects of the other variables listed. Variables
which remain significant in the multiple regression
can be said to have independent statistically
significant effects on the outcome in question.
As the majority of trial participants did not
require adjuvant CT and because of the observed
extensive effect of CT on QOL, the regression
analysis was repeated including pair-wise interac-
tions between CT and the other independent
variables. A further subgroup analysis investigated
associations between clinical variables and QOL
parameters separately for ageo50 andX50 years,
to differentiate between factors affecting pre- and
post-menopausal women, respectively. For all
other analyses age was treated as a continuous
variable. Missing items have been scored according
to EORTC QLQ-C30 scoring manual.22
Body image scale (BIS)
The 10 BIS item scores from 0 (‘none’) to 3 (‘very
much’) were summed to give an overall total
between 0 (best body image) and 30 (worst body
image). The same methods for describing data and
inter-group comparison were used as above.
Hospital anxiety and depression scale (HADS)
The HADS anxiety and depression subscale scores
were categorised as 0–7 (normal), 8–10 (borderline
anxious/depressed) and X11 (probable case anxi-
ety/depression) according to recommended thresh-
olds.21,23 Comparisons between categories of the
prognostic factors listed above were made using
the appropriate w2-test. In order to investigate the
effect of confounding on observed associations,
multiple logistic regression was used. The model
included all prognostic factors listed above, and
the outcome variables of anxiety and depression
were grouped into two categories for the multiple
logistic regression analysis (0–7 vs. X8). The
numbers of patients scoringX11 were small, which
precluded using all three categories of anxiety and
depression in a multiple regression. The p-values
from the multiple logistic regression indicate the
significance of each variable after allowing for the
effects of the other variables listed.
ARTICLE IN PRESS
Table 1 (continued )
Patient characteristic Number of patients (%)
Side of primary
Left 1147 (51.9)
Right 1061 (48.1)
Pathological tumour size (cm)
0–0.9 296 (13.4)
1.0–1.9 1002 (45.4)
2.0–2.9 610 (27.6)
4 3.0 283 (12.8)
Unknown 17 (0.8)
P. Hopwood et al.244The distributions of many of the QOL subscales
were skewed, but no satisfactory transformation
could be found to normalise the data. Means and
standard deviations (SD), together with the median
and interquartile range (IQR) have been presented
in order to facilitate comparison with other
published data. The univariate analyses were
repeated using non-parametric tests, and similar
results were obtained (data not presented). To
make some allowance for chance findings due to
the large number of significance tests carried out,
the cut-off for statistical significance was set to a
more stringent level at p ¼ 0.01.Tumour grade
1 516 (23.4)
2 1030 (46.6)
3 611 (27.7)
Unknown 51 (2.3)
Histological type
Ductal 1722 (78.0)
Lobular 282 (12.8)
Mixed ductal and
lobular
47 (2.1)
Special typesy 113 (5.1)
Not reported 44 (1.9)
Node status
Positive 692 (31.3)
Negative 1444 (65.4)
Unknown 72 (3.3)
Axillary surgery
None 64 (2.9)Results
A total of 2180 patients (98.7% of women accrued)
provided baseline data. Reasons for non-compli-
ance included change of treatment decision, with-
drawal from trial and failure to complete
questionnaires. Completeness of responses on QOL
scales was 99%, apart from the BIS, which was 96%.
The geographic and age distributions of START
QOL patients were comparable with the national
data for breast cancer in the UK per year;24 details
of ethnic groups were not available as this
information was not routinely collected in the
trial. Patient and clinical characteristics at baseline
are shown in Table 1. Three quarters of the patients
were randomised within 19.6 weeks of surgery; ofTable 1 Demographic and clinical characteristics
of 2208 patients in the START QOL study.
Patient characteristic Number of patients (%)
Age
20–29 11 (0.5)
30–39 116 (5.3)
40–49 391 (17.7)
50–59 858 (38.9)
60–69 573 (26.0)
70–79 241 (10.9)
80–89 18 (0.8)
Mean (SD) 56.9 (10.4)
Median (IQR) [range] 56.5 (50.5–63.9) [26–87]
Surgery
Wide local excision 1831 (82.9)
Mastectomy 377 (17.1)
Time since surgery (weeks)
0–4 450 (20.4)
5–9 799 (36.2)
10–19 417 (18.9)
4 20 542 (24.5)
Median (IQR) 8.9 (5.6–19.6)
Axillary clearance 1518 (68.8)
Axillary sampling 584 (26.4)
Sentinel node biopsy 38 (1.7)
Unknown 4 (0.2)
Adjuvant treatment
None 177 (8.0)
Endocrine therapyz 1296 (58.7)
Chemotherapy 221 (10.0)
Endocrine therapyy
and chemotherapy
514 (23.3)
WLE includes patients who had undergone quadran-
tectomy (1), partial mastectomy (4), lumpectomy (1) and
radiologically guided excision biopsy (8).
ySpecial types include tubular and medullary tumours.
z40 patients received endocrine therapy with drugs
other than tamoxifen.
y2 patients received endocrine therapy with drugs other
than tamoxifen.the 542 (25%) randomised more than 20 weeks
following surgery, almost all received adjuvant
chemotherapy (CT) prior to radiotherapy. The
protocol required a minimum of 2 weeks between
the end of CTand start of radiotherapy: the median
interval (IQR) was 35 (25–56) days.
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QOL in early breast cancer 245Three significant interactions were observed
between type of treatment and time from surgery.
First, patients not receiving chemotherapy were
randomised earlier than those receiving it (median
6.7 weeks versus 24.1 weeks, po0.001). Second,
patients undergoing wide local excision (WLE) were
randomised earlier than those having mastectomy
(median 8.3 weeks versus 16.8 weeks, po0.001).
Third, mastectomy patients were more likely to
receive chemotherapy than those who had wide
local excision (62.7% versus 28.5%, po0.001).Key QL domains: body image, sexual
functioning and psychological distress
Body image (BIS)
Over 50% women had no body image concerns
(summary scores of zero) as shown in Fig. 1.
However, scores for women undergoing mastect-
omy (Mx) (median 7; (IQR 3–12)) were significantly
worse than those treated by WLE (median 3; (IQR
0-7), po0.001). Further, scores for women on CT,
(with or without concomitant ET), were signifi-
cantly higher than those women not receiving
systemic therapy (ST), (CT: median 7.0; (IQR
3-13); vs. no ST: median 2.0; (IQR 0-6), po0.001).
Favourable BIS scores were also seen for women
who received endocrine therapy alone (median 2.0;
(IQR0-5)).
The impact of CT was largely explained by the
effect of distress due to hair loss; when CT and the
item ‘distress over hair loss’ were both included in
a regression model for BIS, only the effect for
‘distress due to hair loss’ remained significant. In
multiple regression, type of surgery, age and
CT remained highly statistically significant (all
po0.001), as shown in Table 2.54.6
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Figure 1 Distribution of baseline Body Image Scale
summary scores (higher scores indicate worse body
image).Sexual functioning (SEF) and sexual enjoyment
(SEE), (BR23)
Of 2087 patients who completed the sexual
functioning questions (95.7% of all patients com-
pleting BR23), 1164 (56%) reported having no
interest in sex and 54% reported being sexually
inactive. Descriptive statistics are shown in Table 3.
Of 848 sexually active patients, 5% reported that
sex was not enjoyable, whereas enjoyment was
described as ‘a little’, ‘quite a bit’ or ‘very much’
by 34%, 39% and 22% women, respectively.
Allowing for all variables in the multiple regres-
sion, age and having chemotherapy were significant
(po0.001 for SEF and p ¼ 0.006 for SEE). Of note,
there was no independent effect of type surgery on
sexual functioning (Table 2).
Anxiety and depression (HADS)
The levels of anxiety and depression were calcu-
lated for each subscale. The median anxiety
subscale score was 5.0 (IQR 3–8) and the median
depression score was 2 (IQR 1–5). The prevalence of
anxiety was higher than for depression; two thirds
(1468, 67.6%) of patients scored in the normal
range for anxiety, 391 (18.0%) were in the border-
line range and 313 (14.4%) were probable cases,
whereas 88.1% of patients (n ¼ 1910) scored in the
normal range for depression, 8.9% (192) were in the
borderline range and 3.1% (67) were probable
cases. There was a higher percentage of ‘cases’ in
patients who had received CT (po0.001). In multi-
ple regression, low anxiety was associated with
increased age but no factors had a significant effect
on depression scores (Table 2).
Physical domains: breast and arm symptoms
(EORTC BR23), physical functioning (EORTC
QLQ-C30)
Breast symptoms
Almost two thirds of patients reported pain in the
breast area, 34.9% had swelling in the breast area,
over half reported over-sensitivity and 22% had skin
problems (Table 3). In the multiple regression
analysis, time since surgery, age and CT were
significantly associated with breast symptoms as
shown in Table 2. Type of surgery and ET had no
effect.
Arm symptoms
Significant effects were observed for type of
surgery (fewer symptoms for Mx patients,
p ¼ 0.01), time since surgery (fewer symptoms
with increased time since surgery, po0.001 for
ARTICLE IN PRESS
Table 2 Impact of clinical factors and age on baseline QOL parameters.
Functional subscale or
symptoms item
Type of
surgery
Time since
surgery
Chemotherapy Endocrine
therapy
Age
EORTC QLQ-C30 functional subscale:
Physical 0.02 0.27 0.14 0.08 o0.001
Role 0.03 o0.001 o0.001 0.63 0.38
Emotional 0.58 0.28 0.23 0.78 o0.001
Cognitive 0.94 0.06 0.29 0.86 0.002
Social 0.65 0.006 o0.001 0.36 o0.001
EORTC QLQ-C30 symptoms:
Fatigue 0.56 0.16 o0.001 0.17 0.66
Nausea/vomiting 0.24 0.78 o0.001 0.25 0.01
Pain 0.58 o0.001 0.01 0.26 0.005
Dyspnoea 0.72 0.01 o0.001 0.45 o0.001
Insomnia 0.72 0.59 0.95 0.17 o0.001
Appetite loss 0.01 0.80 0.01 0.51 0.99
Constipation 0.46 0.10 o0.001 0.81 0.04
Diarrhoea 0.04 0.006 0.002 0.20 0.54
Financial difficulties 0.90 0.68 0.07 0.67 o0.001
Global health 0.96 0.14 o0.001 0.11 0.73
Global QL 0.30 0.02 o0.001 0.12 0.54
EORTC BR-23:
Sexual functioning 0.03 0.14 o0.001 0.23 o0.001
Sexual enjoyment 0.96 0.77 0.006 0.96 o0.001
Systemic therapy side
effects
0.19 0.36 o0.001 0.54 0.08
Upset by hair loss 0.77 0.001 o0.001 0.77 0.03
Breast symptoms 0.30 o0.001 0.003 0.96 0.001
Arm symptoms 0.007 o0.001 0.55 0.05 o0.001
Future perspective 0.19 0.02 0.001 0.43 o0.001
Body image scale (10 item) o0.001 0.29 o0.001 0.53 o0.001
HADS anxiety 0.45 0.26 0.97 0.48 o0.001
HADS depression 0.73 0.22 0.19 0.49 0.21
p-values represent significance of F-test (likelihood ratio test for HADS anxiety and depression) obtained from a multiple
regression model including terms for age, type of surgery, time since surgery, chemotherapy and tamoxifen.
For time since surgery and age the p-values correspond to trend tests.
p-values considered to be statistically significant (pp0.01) are highlighted in bold.
Table shows p-values obtained from multiple regression analysis including all treatment variables and age.
Directions of statistically significant effects were as follows:
Type of surgery: scores for appetite loss and body image concerns were worse for mastectomy patients; arm symptoms were
worse for WLE patients.
Time since surgery: scores for role functioning, social functioning, pain, upset by hair loss, breast symptoms and arm symptoms
improved as time from surgery increased; scores for diarrhoea, were worse with increasing time.
Chemotherapy: scores for breast symptoms were better in patients who had received chemotherapy; scores for all other
significant QL parameters were worse.
Age: scores for physical functioning, sexual functioning, sexual enjoyment were worse with increasing age; scores for all other
significant variables were better with increasing age.
P. Hopwood et al.246trend), and age (fewer symptoms in the youngest
and oldest women, p ¼ 0.001), (see Table 2).
Shoulder stiffness (protocol item) was reported as
‘a little’, ‘quite a bit’ or ‘very much’ by 30%, 7%
and 2% patients, respectively, 60% being symptom
free.
Standardised item scores for the full breast
cancer module are shown in Table 3.Physical functioning (EORTC QLQ C-30)
The distribution of physical functioning (PF) scores
is presented in Fig. 2 and descriptive statistics are
presented in Table 4. These showed overall high
levels of PF. Only older age had a significant
association with worse PF in the multiple regression
analysis (Table 2), although the difference in
median PF scores across age categories was modest.
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Table 3 Baseline standardised scores for functional and symptom scales from EORTC BR23 Breast Cancer
Module.
Scale from EORTC BR23 N Mean (SD) Median (IQR)
Functional scales
Sexual function 2087 19.2 (23.0) 16.7 (0–33.3)
Sexual enjoyment 848 59.1 (28.2) 66.7 (33.3–66.7)
Future perspective 2149 54.8 (29.4) 66.7 (33.3–66.7)
Body image (4 items) 2153 78.1 (25.8) 83.3 (66.7–100.0)
Symptom scales/items
Systemic therapy side effects 2174 20.9 (17.2) 19.0 (9.5–28.6)
Arm symptoms 2172 21.2 (19.8) 22.2 (11.1–33.3)
Upset by hair loss 547 50.6 (36.2) 33.3 (33.3–100.0)
Shoulder stiffnessy 2169 16.8 (23.7) 0 (0–33.3)
Breast symptoms 2170 18.5 (16.8) 16.7 (8.3–25.0)
BR23 Breast symptoms N Item frequencyz
Pain 270 1390 (64.1%)
Swelling 2155 753 (34.9%)
Sensitivity 2163 1190 (55.0%)
Skin problems 2168 488 (22.5%)
SD, standard deviation; IQR, interquartile range.
High scores on functional scales indicate high levels of functioning, whereas high scores on the symptom scales and items
indicate high levels of symptoms.
Four items from the BR23 have been combined with the 6 additional items that make up the 10-item Body Image Scale,
reported separately in Table 4.
yProtocol item. 857 patients (39.5%) reported some degree of shoulder stiffness.
zIndividual items that comprise the breast symptoms summary score. Number (%) of patients reporting some degree of each
individual symptom are shown.
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Figure 2 Distribution of baseline EORTC QLQ-C30 physi-
cal functioning subscale scores (higher scores indicate
better physical functioning).
QOL in early breast cancer 247Global health and global QL (EORTC QLQ-C30)
The distribution of scores for global health and
global QL showed that the majority of patients
recorded good or high overall QOL. Interestingly,
the only significant clinical factor to affect global
health and global QOL was receiving chemotherapy
(see Table 2).
Other QOL domains and symptoms (EORTC QLQ-
C30)
Standardised scores for the other four functional
scales (role, emotional, cognitive and social func-
tioning) are shown in Table 4. Also shown are mean
standardised scores for the symptom scales and
items. Results of the multiple regression analyses
are summarised in Table 2.
Most women had moderately good to high levels
of functioning and scores were comparable with
EORTC reference values. In multiple regression,
time from surgery, CT and age were the main
effects. Worse cognitive functioning and better
emotional functioning were associated with in-
creased age, but the absolute difference in scores
across age was small and may have been of little or
no clinical significance. For role and social func-tioning, improvement was observed with increased
time from surgery but worse scores were associated
with CT. Increased age was associated with better
social functioning but worse physical functioning,
whereas CT rather than age was associated with
increased fatigue (Table 2). Younger women re-
ported more physical symptoms, social and finan-
cial difficulties.
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Table 4 Baseline standardised scores for functional and symptom scales from the EORTC QLQ-C30 core
questionnaire.
Scale from EORTC QLQ-C30 N Mean (SD) Median (IQR)
Functional scales
Physical functioning 2176 83.8 (16.7) 86.7 (73.3–93.3)
Role functioning 2174 70.1 (28.7) 66.7 (50.0–100.0)
Emotional functioning 2173 75.3 (21.6) 75.0 (66.7–91.7)
Cognitive functioning 2175 81.9 (21.0) 83.3 (66.7–100.0)
Social functioning 2174 75.6 (25.9) 83.3 (66.7–100.0)
Symptom scales/items
Fatigue 2176 33.1 (22.7) 33.3 (22.2–44.4)
Nausea and vomiting 2176 7.1 (14.9) 0 (0–16.7)
Pain 2176 20.9 (23.9) 16.7 (0–33.3)
Dyspnoea 2163 13.4 (22.0) 0 (0–33.3)
Insomnia 2164 33.8 (31.2) 33.3 (0–66.7)
Appetite loss 2171 12.1 (23.0) 0 (0–33.3)
Constipation 2164 14.7 (24.5) 0 (0–33.3)
Diarrhoea 2168 6.3 (16.3) 0 (0–0)
Financial difficulties 2171 15.4 (27.5) 0 (0–33.3)
Global health 2169 66.8 (20.0) 66.7 (50.0–83.3)
Global QL 2168 69.8 (21.2) 66.7 (50.0–83.3)
SD, standard deviation; IQR, interquartile range.
High scores on functional scales indicate high levels of functioning, whereas high scores on the symptom scales and items
indicate high symptom severity.
P. Hopwood et al.248Summary of impact of age and clinical variables
on QOL symptoms and domains
A summary of the effects of age and clinical
variable is shown in Table 2; these effects were
wide ranging involving nearly all areas of function
and symptoms. Age and CT had the most extensive
effects whereas ET had no significant effect on key
QOL variables. More QOL parameters were ad-
versely affected by younger age than older age, as
detailed in the table.
Subgroup analysis and interactions
Significant interactions were observed between CT
and time since surgery on the scores for physical,
role and social functioning, fatigue, pain and
appetite loss, breast and arm symptoms, global
health and global QL. Improvements were found in
fatigue, appetitive loss, global health and global QL
for the NoCT group but not for the CT group. No
effect of endocrine therapy on any QL domains or
symptoms was found for the NoCT group.
Impact of treatment on women aged o50 years
Five hundred and eighteen (23.5%) were aged under
50 years at the time of baseline assessment
(broadly considered pre-menopausal). Associations
between clinical variables and QOL parameters
were examined separately for women aged o50years and those aged X50 years, and although no
consistent patterns were found, the adverse effect
of chemotherapy on sexual functioning appeared to
be greater for the younger women (p ¼ 0.04).
However, overall, mean SEF and SEE scores were
more favourable for women o50 (SEF: 27.2; SEE:
62.5) compared to women Z50 (SEF: 16.6, SEE:
57.3).
Psychological morbidity prevalence rates were
significantly higher for younger women (anxiety:
41.5% of womeno50 years scoredZ8 compared with
29.6% of women Z50 years, po0.001; depression:
14.9% of womeno50 years scoredZ8 compared with
11.0% of women Z50 years, p ¼ 0.02). BIS scores
were also significantly higher for women o50 years
(median7, (IQR 3–13)); compared with those Z50
years (median 2, (IQR 0–6), po0.001), indicating more
body image concern.Discussion
Findings from this large patient population high-
light the important effects of age, type of surgery
and adjuvant CT on the QOL in women about to
start radiotherapy, whilst allowing for time elapsed
since first treatment. Of particular note was the
dominant effect of adjuvant chemotherapy on a
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showed that CT extenuated the otherwise bene-
ficial effect of time from surgery on a range of QOL
domains, so that the majority of patients who did
not receive CT had better QOL over time. Interest-
ingly, despite the deleterious effect of CT on QOL,
there was no effect of CT on psychological distress.
Patients who were younger and who had received
CT also had a worse future perspective, possibly
consistent with their less favourable prognosis and
the wide ranging impact of treatment on them.
Overall, global health/QOL ratings were only
affected by CT, emphasising the adverse impact of
this systemic therapy over and above surgery or
endocrine treatment for the subgroup of women
who received it.
As expected, there was a clinically significant
increase in body image problems for women
undergoing Mx compared with WLE, as extensively
reported in the literature.7,20,26,27 The effect of
chemotherapy related hair loss on body image has
been reported28 but a precise measure of its impact
in comparison to other treatment effects has been
lacking. It is possible that weight gain due to CT
(not assessed in this trial) as well as distress due to
hair loss contributed to our result. Given improve-
ments to body image outcomes from the use of
conservative surgery, it is particularly important to
identify other factors that may confound this
result. Mediating factors, (not assessed here), such
as the importance of appearance to an individual
patient, and preference for the type of breast
surgery, can also determine adjustment to body
image changes and should be also be taken into
account clinically. Arm symptoms were significantly
worse for women treated by WLE rather than Mx,
but no difference in overall physical functioning
was attributable to type of surgery in the regression
analysis, which is contrary to other findings.16 This
may reflect the importance of controlling for other
key variables when investigating these effects.
Levels of psychological distress were generally
comparable with other published reports of cancer
patients,29–32 and population samples,31,33,34 sug-
gesting good psychological adaptation for the
majority of women, as reported recently by Ganz
et al.16 Emotional functioning was protected by
older age but unaffected by clinical factors,
despite the long and complex treatments involved
for some women. However, the impacts of treat-
ment were wide ranging in other aspects of QOL.
Levels of sexual activity and enjoyment were low
overall, as reported in other published data.7,19,25
Few comparison data with age-matched healthy
women are available30 but results may be similar to
population samples. There was no significant effectof Mx on SEF, which was unexpected given earlier
studies in this area. However, details of sexual
activity before breast surgery were unavailable in
this trial, to exclude a change over time from
diagnosis. Adjuvant CT had a significant impact on
SEF and SEE, regardless of type of surgery, as
reported by Ganz et al.,16 particularly the sexual
well-being of younger women. Younger women who
remained pre-menopausal, through not having che-
motherapy, had the best sexual functioning, suggest-
ing the negative impact of a transition through an
artificial menopause. These results suggest that
longer-term effects reported in the literature may
be apparent early in the treatment pathway.
In contrast to chemotherapy, endocrine therapy
had no significant effect on QOL domains when
other factors were controlled for, but this probably
reflects the short prescribing time; outcomes at 2
and 5-years follow-up will be more informative.
Several QOL domains varied with time from
surgery or age and these factors should be
controlled for in other QOL analyses. The effect
of age on anxiety and sexual activity may represent
a moderating effect of age-related reporting, but
PF and other symptoms are likely to represent more
direct effects. Physical functioning was well pre-
served for the majority of women, with no
significant worsening with chemotherapy, in con-
trast to other research,2 but the small age effect
confirmed the findings of Fehlauer et al.35 The
range of scores for other EORTC functional sub-
scales were comparable with published reference
data36 and contemporary publications.25 Frequen-
cies of low levels of functioning were comparable
to or better than reference values but the impact
of co-morbidity on QOL domains may be more
apparent over time and will be reported separately.
This QOL analysis is based on a large, represen-
tative sample of women in the United Kingdom and
covers a wide age range, so that we can have
confidence in the results. Findings represent the
impact of contemporary surgical methods and
adjuvant systemic treatments, in contrast to many
earlier studies in this field. Care has been taken to
investigate interactions to best explain the find-
ings. A limitation in this approach is that the trial
design did not afford the chance for a pre-operative
assessment of QOL which may limit the interpreta-
tion of some results.Conclusions
A broad and detailed description of QOL has been
presented and the independent adverse effects of
age and primary treatments on QOL determined,
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parameters were better for the majority of women
who had undergone WLE and avoided CT. The
impact of surgery was narrow in QOL terms
compared with CT and age effects, but all of these
factors can have a clinically significant impact.
Treating teams need to be aware of the differential
effects of age and primary treatments for breast
cancer in women presenting for radiotherapy, in
order to offer additional support and intervention
for those at increased risk of poor QOL.Acknowledgements
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